Replies to post #488870 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

I do see the bigger picture as reflected in my some 35% chance of approval. A big improvement over my original about 20-25% and much much better than Doc's 4% - admittedly not as good as some other dreams.

[williamssc]

And everyday for years. As we move along those posts are now like the ticking of a clock no one pays attention too. We'll soon see what the EMA has to say. That's where the rubber meets the road.

[boi568]

"You repeatedly demonstrate that you are unable to see the big picture and only focus on rigid regulatory requirements that should be evaluated in light of an disease where current SOC is simply not acceptable."

You're giving his argument too much credit. There is no EMA "rigid regulatory requirement" that rules out Anavex's 2b/3 trial for size and duration, and no EMA requirement, either, for ADL to be used as a primary endpoint in an early AD trial. He is asserting regulatory preconditions that don't exist.